MedTrace Logo

Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients

NCT01103622 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-01-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether AZD1656 will affect the pharmacokinetics (PK) of digoxin in type 2 diabetes mellitus (T2DM) patients.

Conditions

Interventions

DRUG

AZD1656

Oral tablet bd, step-wise increased dosage

DRUG

Digoxin

Oral tablet od on Day 4

DRUG

Placebo

Oral tablet bd, step-wise increased dosage

Sponsors & Collaborators

Principal Investigators

  • Stanko Skrtic · AstraZeneca

  • Christoph Kapitza · Profil Institut für Stoffwechselforschung GmbH

  • Mirjana Kujacic · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01103622 on ClinicalTrials.gov